Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer

L. Garland, L. A. Robinson, Henry Wagner Jr.

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.

Original languageEnglish (US)
Pages (from-to)69-100
Number of pages32
JournalChest Surgery Clinics of North America
Volume11
Issue number1
StatePublished - Mar 26 2001

Fingerprint

Non-Small Cell Lung Carcinoma
Poisons
Thorax
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

@article{04d4b5bb74dd49cf86efd33043ce4300,
title = "Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer",
abstract = "Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.",
author = "L. Garland and Robinson, {L. A.} and {Wagner Jr.}, Henry",
year = "2001",
month = "3",
day = "26",
language = "English (US)",
volume = "11",
pages = "69--100",
journal = "Thoracic Surgery Clinics",
issn = "1547-4127",
publisher = "W.B. Saunders Ltd",
number = "1",

}

Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer. / Garland, L.; Robinson, L. A.; Wagner Jr., Henry.

In: Chest Surgery Clinics of North America, Vol. 11, No. 1, 26.03.2001, p. 69-100.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer

AU - Garland, L.

AU - Robinson, L. A.

AU - Wagner Jr., Henry

PY - 2001/3/26

Y1 - 2001/3/26

N2 - Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.

AB - Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=0035103952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035103952&partnerID=8YFLogxK

M3 - Review article

VL - 11

SP - 69

EP - 100

JO - Thoracic Surgery Clinics

JF - Thoracic Surgery Clinics

SN - 1547-4127

IS - 1

ER -